Document is current

Article History

First Online: 16 December 2025

Declarations

:

: MB reports research grants from the German Research Foundation (DFG), the German Federal Ministry of Research, Technology and Space (BMFTR) and the EU. His department received funding for clinical trials from Roche, Solvamed GmbH and BioAegis Therapeutics. MB received honoraria for lectures and consulting fees from Artcline GmbH, BRAHMS (ThermoFisher), Bayer AG, Volition, Hillrom Iberia (Baxter), DiaSorin Deutschland GmbH and Deepull Diagnostics. MB is co-owner of several patents (WO 2017041782 A1, WO 2015035974 A1, DE 102006027842 A1, WO 2012013247 A1, WO 2011080184 A1), co-applicant for a pending patent on biomarkers for the prognosis of CAP, and shareholder in SmartDyeLivery GmbH. The department of PT received funding for clinical trials from bioMerieux and Vantive. PT received consulting fees and honoraria for lectures from Biomerieux, Baxter and ThermoFisher and participates in a ThermoFisher advisory board. He is co-owner of a patent on endotoxin virulence (patent holder CNRS). MS reports grants for a clinical trial to his department form Gentian. MS received consulting fees from Biotest as well as honoraria for lectures from Biomerieux, AOP and Pfizer. MS is co-owner of a patent on an ischaemia–reperfusion drug and of a pending patent application (patent holder UCL). He participates in Advisory Boards of Safeguard Biosystems, Aptarion, Roche Diagnostics, Deltex Medical, Sanofi, Matisse, Deepull, Volition, Bayer, and Radiometer.